Memantine treatment reduces the incidence of flaccid paralysis in a zika virus mouse model of temporary paralysis with similarities to Guillain-Barré syndrome

Venkatraman Siddharthan¹, Hong Wang¹, Alexandre LR de Oliveira², Xin Dai³ and John D Morrey¹

Abstract
Clinical evidence suggests that Zika virus contributes to Guillain-Barré syndrome that causes temporary paralysis. We utilized a recently described Zika virus mouse model of temporary flaccid paralysis to address the hypothesis that treatment with an N-methyl-D-aspartate receptor antagonist, memantine, can reduce the incidence of paralysis. Aged interferon alpha/beta-receptor knockout mice were used because of their sublethal susceptibility to Zika virus infection. Fifteen to twenty-five percent of mice infected with a Puerto Rico strain of Zika virus develop acute flaccid paralysis beginning at days 8–9 and peaked at days 10–12. Mice recover from paralysis within a week of onset. In two independent studies, twice daily oral administration of memantine at 60 mg/kg/day on days 4 through 9 after viral challenge significantly reduced the incidence of paralysis. No efficacy was observed with treatments from days 9 through 12. Memantine treatment in cell culture or mice did not affect viral titers. These data indicate that early treatment of memantine before onset of paralysis is efficacious, but treatments beyond the onset of paralysis were not efficacious. The effect of this N-methyl-D-aspartate receptor antagonist on the incidence of Zika virus-induced paralysis may provide guidance for investigations on the mechanism of paralysis.

Keywords
Memantine, zika virus, paralysis, Guillain-Barré syndrome, NMDA receptor antagonist, N-methyl-D-aspartate receptor

Introduction
Congenital Zika syndrome and Guillain-Barré syndrome in adults are two serious outcomes associated with Zika virus outbreaks.¹⁻⁴ Guillain-Barré syndrome is a reversible, acute peripheral neuropathy involving temporary paralysis. The mechanism by which Zika virus causes paralysis in Guillain-Barré syndrome is unknown. A recent mouse model of Zika virus-induced temporary paralysis has provided an opportunity to evaluate cellular mechanisms.⁵ Since Zika virus does not cause robust disease in adult laboratory mice, interferon αβ-receptor (IFNAR⁻/⁻) knockout mice were used. Infection is lethal in young IFNAR⁻/⁻ mice, but infection in aged mice greater than 4-months-old is sublethal. In these mice, hindlimb acute flaccid paralysis developed in 15–25% of infected mice beginning on days 8–9 and peaking on days 10–11. Within a week of onset, mice recover from paralysis.

¹Department of Animal, Dairy, and Veterinary Sciences, Institute for Antiviral Research, Utah State University, Logan, UT, USA
²Institute of Biology, University of Campinas, Campinas, SP, Brazil
³Utah Agricultural Experiment Station, College of Agriculture, Utah State University, Logan, UT, USA

Corresponding author:
John D Morrey, Department of Animal, Dairy, and Veterinary Sciences, Institute for Antiviral Research, Utah State University, 5600 Old Main Hill, Room 202, Logan, UT 84322-5600, USA.
Email: john.morrey@usu.edu
Unlike more pathogenic flaviviruses, like West Nile virus or Japanese encephalitis virus, that infect and destroy motor neurons in the spinal cord, Zika virus infection in aged IFNAR−/− mice does not destroy motor neurons. Zika virus immunoreactivity cannot be readily detected with colocalization of motor neuron-immunoreactive markers in the lumbosacral spinal cords of paralyzed mice, yet there is some Zika virus immunoreactivity outside of motor neurons. Ultrastructural analysis by electron microscopy reveal that pre-synaptic terminals becomes detached or retracted from alpha-motor neurons in paralyzed mice at a statistically significant level. The synapses are then re-associated upon recovery of paralysis. The biochemical mechanisms by which these events occur is uninvestigated.

To begin mechanistic studies, we evaluated memantine for efficacy. Memantine is an N-methyl-D-aspartate receptor antagonist and is an indication for treatment of moderate to severe Alzheimer’s disease. The premise for this efficacy study is that memantine and other agonists (dizocilpine (MK-801), agmatine sulfate, ifenprodil) prevent neuronal death in cell culture without affecting Zika virus replication, and prevent the increase of virus induced-intraocular pressure and reduce neurodegeneration in the brains of interferon-receptor deficient mice.6,7 In a subsequent neuronal cell culture study, blocking of the N-methyl-D-aspartate receptor by ifenprodil reduced neuronal cell death coincident with reduced influx of Ca2+.8

Methods
In the first of three memantine treatment experiments, male and female IFNAR−/− mice at 4.2- to 5.3-months-old were block-randomized between groups according to weight and gender and injected subcutaneously (s.c.) on both sides for a total of 1,340 pfu of ZIKV per mouse (PRVABC59, Human/2015/Puerto Rico, BEI Resources passed age 2 times in Vero 76 cells in MEM with 50 µg/mL gentamicin) or sham (uninfected cells prepared and diluted the same as the viral inoculum). Although one strain of ZIKV were not evaluated, there was no a priori reason to believe that memantine would be efficacious with other viral strains because memantine is probably targeting cellular processes, and not the virus specifically. Beginning at 4 days after viral challenge, mice were treated twice daily by oral gavage (p.o.). Treatments continued through day 9. Volumes of treatment solution were adjusted for weights of individual mice to achieve 60 mg/kg/day dosage. The numbers of mice were n = 16 for the ZIKV-memantine group, n = 14 for the ZIKV-vehicle group, n = 3 for the sham-memantine group, and n = 3 for the sham-vehicle group. Details of the other two experiments shown in figure legends are similar to this first experiment. Data were analyzed using generalized estimating equation with compound symmetry structure of the working correlation matrix. Binary outcome of motor deficit is modeled with logit link function. Analysis was performed using PROC GENMOD in SAS/STAT 15.1 (SAS Institute Inc., Cary, NC). Animal studies were accordance with the approval of the Institutional Animal Care and Use Committee of Utah State University.

Mice were analyzed using the viral paresis scale9 for signs of tail and hindlimb paresis/paralysis using a sensitive, open-field assay modified from the Basso Mouse Scale used to assess paralysis in spinal cord-injured mice10 and a test used to track paralysis in amyotrophic lateral sclerosis mouse models.11 Each mouse was placed on a tabletop and allowed to roam freely for 4 minutes. Hindlimb function was scored on a 7-point scale9 by researchers who were blinded to the infection status of each group. In this study, mice with VPS of 5 or 6 were paralyzed in either or both hindlimbs.

Results
Memantine treated from day 4 through day 9 significantly reduced the prevalence of paralysis (p = 0.020) (Figure 1(a)). The number of paralysis-mouse-days was also statistically reduced at p = 0.0010 and p = 0.0001, respectively (Figure 1(b)). Since the incidences of paralysis of placebo-treated mice (6/18, 33%) was low, the statistical power was weak. To validate the reproducibility of these data, a second independent experiment was performed. We increased the numbers of mice in each infected group from 18 and 20, to 26 each. Even though the incidence of paralysis in the placebo-treated group was again low at 19% (5/26), memantine was still efficacious in reducing the prevalence of paralysis (p = 0.040) (Figure 1(d)). We were able to overcome the statistical challenge of a low incidence of paralysis by performing two independent experiments, increasing the number of mice in each infected group to 26, and using an appropriate statistical model. Data were also analyzed by calculating the paralysis-mouse-days. By Fischer's exact P stack analysis, memantine also significantly improved the paralysis outcome (Figure 1(e)) (p = 0.0089, respectively). This statistical test of the percentage of paralyzed mice also revealed statistical significance (p = 0.0381) in experiment #1, but not experiment #2. As previously observed,5 most animals survive (Figure 1(c) and (f)) and recover from paralysis (Figure 1(a) and (d)).

To determine if memantine could treat existing paralysis, treatment was initiated at day 9 and extended through peak days of paralysis through day 14.
However, memantine was ineffective; statistical differences in paralysis were not observed (Figure 2).

We eliminated the possibility that memantine's mechanism of action was to reduce viral load as measured in cell culture (50% effective concentration $>7.8 \text{ mg/mL}$; 50% cytotoxic concentration $= 7.8 \text{ mg/mL}$) or in the spinal cords of mice (Figure 3), which confirmed previous results observed in primary neuronal cell culture. We were unable to determine whether the reduction in paralysis was due to a decrease in viral load or another mechanism.

**Discussion**

The primary purpose of this study was to investigate the possible role of N-methyl-D-aspartate receptor in the development of temporary paralysis caused by ZIKV using memantine, an inhibitor of this receptor. In two independent experiments, memantine reduced the incidence of paralysis, which suggests that activation of this receptor is associated with paralysis. A distinguishing pathological event in this mouse model is that pre-synaptic terminals becomes detached or retracted from alpha-motor neurons in paralyzed mice. The synapses are then re-associated upon recovery of paralysis. A hypothesis for future studies, therefore, is that glutamate excitotoxicity mediated by N-methyl-D-aspartate receptors signals synaptic retraction and paralysis, and that resolution of glutamate excitotoxicity might reverse the paralysis of ZIKV-induced Guillain-Barré syndrome.

A limitation of the study is the necessary use of interferon non-responsive mice. A series of publications following the ZIKV outbreak found that adult wild-type laboratory mice are not susceptible to ZIKV infection, but mice that lack type 1 and/or type 2 interferon receptors are susceptible to lethal infection. These interferon non-responsive models do have flaws, but they may also have some relevance to human ZIKV infections. Like many viruses, ZIKV gains advantages in human hosts by inhibiting interferon responses. Because the virus may not be able to inhibit mouse-specific interferon pathways, blocking interferon response in transgenic mice allows the virus to similarly replicate as it does in human subjects.

**Figure 1.** Memantine (60 mg/kg/day) twice daily oral gavage (p.o.) treatments on days 4 to 9 after Zika virus challenge reduced the prevalence of (a, d) paralysis and (b, e) paralysis mouse-days in two independent experimental trials. Paralysis was identified in mice having VPS $\geq 5$ on either or both hindlimbs. Paralysis mouse-days were calculated by the number of paralyzed mice on each day between 9 and 12 days for each group divided by the total number of mice on each day between 9 and 12 days per group. (c, f) Survival was high ($>80\%$). The age of the IFNAR$^{-/-}$ mice in experiment #1 were 4.2- to 5.3-months-old. n = 20 ZIKV-memantine group; n = 18 ZIKV-vehicle group; n = 9 sham-memantine group; n = 9 sham-vehicle group.
These data indicate that early treatment of memantine before onset of paralysis is efficacious, but treatments beyond the onset of paralysis were not efficacious. The effect of this N-methyl-D-aspartate receptor antagonist on the incidence of Zika virus-induced paralysis may provide guidance for investigations on the mechanism of paralysis.

Acknowledgements

We thank the following individuals from the Institute for Antiviral Research at Utah State University for their excellent technical assistance: Dallan Blotter for conducting thorough VPS scoring; Brittney Downs, Dallan Blotter and Kade Roberts for performing viral tissue titers, Matthew McKinnon for Zika RT-PCR, Parker Webber for managing IFNAR−/− mouse colony; Ashley Dagley for overseeing technician training and animal studies; Jaxton Birky, Ben Elgan, Carlee Frank, Dallan Blotter, Kade Roberts, Nicole Anderson, Parker Webber and Ryden Crowther for conducting animal studies; and Nicole Anderson for proof-reading the manuscript.

Author’s contribution

JDM, VS and ALRO conceived the study and experimental design. JDM, VS, and HW acquired, analyzed and interpreted the data. XD modeled and analyzed the statistics. JDM wrote the manuscript.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The work was supported by Public Health Service (PHS) research grants 1R21NS090133 to J.D.M. from the National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), and PHS grant 5R33AI101483 and contract HHSN2722010000391/ HHSN27200004 to J.D.M. from the Virology Branch, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Utah Agriculture Research Station research grant UTA01176 to J.D.M., Fundação de Amparo à Pesquisa do Estado de São Paulo – FAPESP, Brazil, proc. 2014/06892-3; Conselho Nacional de Desenvolvimento Científico e Tecnológico – CNPq, Brazil, proc. 303085/2017-7, A.R.L.de O. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
References

1. Counotte MJ, Meili KW, Taghavi K, et al. Zika virus infection as a cause of congenital brain abnormalities and Guillain-Barre syndrome: a living systematic review. *F1000Res* 2019; 8: 1433.

2. CDC concludes Zika causes microcephaly and other birth defects. Atlanta, GA: Centers for Disease Control and Prevention, 2016.

3. Arias A, Torres-Tobar L, Hernandez G, et al. Guillain-Barre syndrome in patients with a recent history of zika in Cucuta, Colombia: a descriptive case series of 19 patients from December 2015 to March 2016. *J Crit Care* 2017; 37: 19–23.

4. Cao-Lormeau VM, Blake A, Mons S, et al. Guillain-Barre syndrome outbreak associated with zika virus infection in French Polynesia: a case-control study. *Lancet* 2016; 387: 1531–1539.

5. Morrey JD, Oliveira ALR, Wang H, et al. Zika virus infection causes temporary paralysis in adult mice with motor neuron synaptic retraction and evidence for proximal peripheral neuropathy. *Sci Rep* 2019; 9: 19531.

6. Costa VV, Del Sarto JL, Rocha RF, et al. N-Methyl-d-Aspartate (NMDA) receptor blockade prevents neuronal death induced by zika virus infection. *mBio* 2017; 8: e00350–17.

7. Sirohi D and Kuhn RJ. Can an FDA-Approved Alzheimer’s drug be repurposed for alleviating neuronal symptoms of zika virus? *mBio* 2017; 8: e00916–17.

8. Olmo IG, Carvalho TG, Costa VV, et al. Zika virus promotes neuronal cell death in a non-cell autonomous manner by triggering the release of neurotoxic factors. *Front Immunol* 2017; 8: 1016.

9. Zukor K, Wang H, Siddharthan V, et al. Zika virus-induced acute myelitis and motor deficits in adult interferon alphabeta/gamma receptor knockout mice. *J Neurovirol* 2018; 24: 273–290.

10. Basso DM, Fisher LC, Anderson AJ, et al. Basso mouse scale for locomotion detects differences in recovery after spinal cord injury in five common mouse strains. *J Neurotrauma* 2006; 23: 635–659.

11. Hatzipetros T, Kidd JD, Moreno AJ, et al. A quick phenotypic neurological scoring system for evaluating disease progression in the SOD1-G93A mouse model of ALS. *JoVE* 2015; (104): 53257.

12. Aliota MT, Caine EA, Walker EC, Larkin KE, Camacho E, Osorio JE. Characterization of Lethal Zika Virus Infection in AG129 Mice. *PLoS neglected tropical diseases* 2016; 10(4): e0004682.

13. Rossi SL, Tesh RB, Azar SR, Muruato AE, Hanley KA, Auguste AJ, et al. Characterization of a Novel Murine Model to Study Zika Virus. *The American journal of tropical medicine and hygiene*. 2016; 94(6): 1362–1369.

14. Zmurko J, Marques RE, Schols D, Verbeken E, Kaptein SJ, Neyts J. The Viral Polymerase Inhibitor 7-Deaza-2’C-Methyladenosine Is a Potent Inhibitor of In Vitro Zika Virus Replication and Delays Disease Progression in a Robust Mouse Infection Model. *PLoS Negl Trop Dis* 2016; 10(5): e0004695.

15. Lazear HM, Govero J, Smith AM, Platt DJ, Fernandez E, Miner JJ, et al. A Mouse Model of Zika Virus Pathogenesis. *Cell Host Microbe* 2016; 19(5): 720–730.

16. Manangeeswaran M, Ireland DD, Verthelyi D, Zika (PRVABC59) Infection Is Associated with T cell Infiltration and Neurodegeneration in CNS of Immunocompetent Neonatal C57Bl/6 Mice. *PLoS pathogens* 2016; 12(11): e1006004.

17. Bowen JR, Quicke KM, Maddur MS, O’Neal JT, McDonald CE, Fedorova NB, et al. Zika Virus Antagonizes Type I Interferon Responses during Infection of Human Dendritic Cells. *PLoS pathogens* 2017; 13(2): e1006164.

18. Best SM. The Many Faces of the Flavivirus NS5 Protein in Antagonism of Type I Interferon Signaling. *J Virol* 2017; 91(3): e01970-16.

19. Schulz KS, Mossman KL. Viral Evasion Strategies in Type I IFN Signaling – A Summary of Recent Developments. *Frontiers in immunology* 2016; 7: 498.

20. Aguirre S, Maestre AM, Pagni S, Patel JR, Savage T, Gutman D, et al. DENV inhibits type I IFN production in infected cells by cleaving human STING. *PLoS pathogens* 2012; 8(10): e1002934.